INTRODUCTION
Qiagen currently sells numerous assays for quantitative measurements of MGMT (methylguanine methyltransferase) methylation status using the pyrosequencing technique. Hs_MGMT_01_PM
PyroMark CpG assay (ref PM 00149702) analyzes 7 CpGs located upstream of DMR1 and DMR2 regions, where methylation has significantly been correlated with expression [1] . This assay must therefore be avoided for a clinical purpose. Two additional assays (ref 970032 and 972032) quantify the methylation levels of CpGs 74 to 78. They are respectively optimized for use with the PyroMark Q24 and Q96. These two similar assays are currently the most widely used and validated pyrosequencing assays [2] . They will be further referred to as PSQ. In 2011, a fourth assay was launched: the Therascreen MGMT Pyro Kit (Thera). This assay, in contrast to the others, is a CEmarked In Vitro Diagnostic Medical Device (CE-IVD) that meets all requirements of the EC Directive 98/79.
Several countries around the world have adopted the international standard ISO 15189, which specifies requirements for quality and competence in medical laboratories. Among the preferred procedures described in this international standard are those specified in the instructions for use of in vitro medical devices. Furthermore, as the steps of validation into the laboratory are less extensive for CE-IVD assays, laboratories tend to favor this type of assay. Thera appears to be a suitable choice for MGMT testing and some studies have reported strong analytical performances for this assay [3, 4] .
However, this assay quantifies the methylation levels of CpGs 76 to 79 instead of CpGs 74 to 78. One of the strengths of PSQ for MGMT testing relies on the several independent studies that are concordant with the threshold levels that discriminate glioblastoma (GBM) patients as being good or poor responders to Temozolomide (TMZ) treatment [2] . As a heterogeneous pattern of methylation can be observed for some tumors, the shift in the CpGs analyzed between the two assays could potentially impact the result (= average methylation percentage of the tested CpGs). It is therefore mandatory to validate the cut-off for the Thera assay.
We have recently performed a prospective dedicated multicenter trial, which allowed us to validate the use of PSQ in a daily practice. For the present study, we analyzed 102 frozen GBM patients from this trial with the Thera assay and compared the results to those obtained previously with the standard PSQ test.
MATERIALS and METHODS

Patients and samples
Samples were analyzed from patients enrolled in a prospective study dedicated to the validation of two techniques to assess MGMT status [5] . Patients were enrolled for this study between the dates of 
Statistical analysis
Statistical analysis was performed using R statistical software (version 2.13.0, http://www.Rproject.org). The function risksetAUC (package risksetROC) in the R statistical software was used to obtain the area under the ROC curve. Additionally, the Harrell's C index [6] was calculated using the validate function (in Design package). To study OS and PFS, cumulative event curves (censored endpoints) were established using the Kaplan-Meier method.
RESULTS
Study population
Among the 112 samples of patients initially analyzed with PSQ, 102 were available for the Thera analysis. The median Progression Free Survival (PFS) for these 102 patients was 9.5 months (8.8 -11.2; 95% CI) and the median Overall survival (OS) was 20.6 months (18.7 -23.0; 95% CI).
Analysis of intra-laboratory reproducibility of Thera
Each control was evaluated in 6 different series. The mean values were 4% for RNS85 (range: 4-4%),
16% for RNS175 (range: 15-17%) and 33% (range: 32-34%) for RNS96. The reproducibility CVs were 5% for RNS175 and 3% for RNS96. All the results were identical for RNS85, which is close to the limits of quantification previously published for pyrosequencing (4%).
Comparison of MGMT methylation results obtained with the 2 kits
The median percentages of methylation for the studied population were 7% when using Thera (range 1-65%) and 8% when using PSQ (range 1-84%) ( Table 1) . A strong correlation was observed for CpG76, 77, 78 and CpG mean analyzed using the PSQ and Thera assays. However, almost systematically, lower results were recorded with Thera, especially for values greater than 20% ( Figure   1 ).
Validation of the pre-defined cut-offs 8% and 12% for Thera
We recently recommended a classification of MGMT promoter methylation status into three subgroups: "unmethylated" (0-8%), "methylated" (13-100%) and a grey zone for patients with intermediate values (9-12%) [5] . The cut-offs 8 and 12% were tested in this series of patients. The percentages of patients classified as "methylated", when employing a cut-off of 8% and 12% for PSQ, were 50% and 44% with AUCROC values of 0.69 for OS (Table 2 ). These data are almost identical to those obtained for the overall population (n=112 patients, 49%, 44% and AUCROC values of 0.69 and 0.70), indicating the absence of bias in the selection of the 102 patients for the present cohort. The percentages of patients classified as "methylated" when employing a cut-off of 8% and 12% for Thera were 45% and 41%, with AUCROC values of 0.68 for OS (Table 2) . With a classification in 3 categories (methylated/unmethylated/grey zone), 93% of patients were identically classified using the two assays. With a binary classification (methylated/unmethylated), 95% and 97% of patients were identically classified with cut-offs of 8% and 12% respectively (Table 3) . Table 4 shows the pyrosequencing results, as well as the time to death and time to progression for the patients differently classified by the two assays.
Kaplan-Meier survival curves displaying the OS of patients dichotomized according to these cut-offs are presented in Figure 2 . At a methylation cut-off of 8%, median OS were 34. [8, 11, 16] . In our study, the higher the cut-off increased, the higher the percentage of discordant cases. For example, values of 25%, 35% and 50% associated with 6%, 9% and 21% of patients having been differently classified within the two techniques.
To validate a clinical cut-off, we tested values of 8 and 12%. 41% of patients had values >12% with Thera compared to 44% with PSQ. 55% of patients had values ≤8% with Thera compared to 50% with PSQ. In all discordant cases except one, result were between 9% and 12% with one assay and >12%
or ≤8% with the other assay. A very good prognostic significance was observed for both assays and both cut-offs. The reduced risk of death in the case of results above 12% was slightly higher with PSQ compared to Thera (HR: 0.27, p<1.00E -06 versus HR: 0.30, p=1.00E
-06
), as we had already reported using a non-company producted PSQ test [15] . For this study, we have not been able to establish the prognosis of patients whose tumors present with percentages of methylation comprise between 9%
and 12%. Since it is for this category of patients that we observed the higher number of discordant cases between the two techniques, we recommend, as for PSQ, to consider patients with a mean methylation percentage ≤ 8% as unmethylated, those with a mean methylation percentage >12% as methylated and those with percentages of methylation between 9% and 12% as being in a grey zone.
An additional study analyzing a series of GBM FFPE samples with Thera found that the optimal cut-off value to dichotomize patients was ≥8% [17] , providing confidence in our choice of thresholds.
In conclusion, Thera and PSQ may both be used to analyze MGMT status in glioblastomas. Intralaboratory reproducibility for Thera was good and others have previously reported a high analytical 
